Clin Kidney J. 2012 Jun;5(3):212-6. doi: 10.1093/ckj/sfs045. Epub 2012 Apr 20.

Regional citrate anticoagulation for slow continuous ultrafiltration: risk of severe metabolic alkalosis.

Clinical kidney journal

Mourad M Alsabbagh, A Ahsan Ejaz, Daniel L Purich, Edward A Ross

PMID: 26069766 PMCID: PMC4400517 DOI: 10.1093/ckj/sfs045

Abstract

BACKGROUND: Slow continuous ultrafiltration (SCUF) is a safe and efficient treatment for fluid overload in patients who are hemodynamically unstable, have low urine output, and are not in need of dialysis or hemofiltration for solute clearance. Sustained anticoagulation is required for these long treatments, thus posing clinically challenges for patients having contraindications to systemic anticoagulation with heparin. Regional citrate anticoagulation would be an alternative option; however, we believed that this would be problematic due to citrate kinetics that predicted the development of metabolic alkalosis.

METHODS: In that patients' serum bicarbonate reached 45 mEq/L and arterial pH rose to 7.59 after just 3 days of SCUF, we developed equations to study this phenomenon. We report here the acid-base balance calculations quantifying base accumulation in SCUF compared to continuous venovenous hemofiltration (CVVH).

RESULTS: This kinetic approach demonstrates the importance of accounting for the high citrate clearance into CVVH hemofiltrate, which prevents development of the alkalosis seen with the relatively low ultrafiltration rates in SCUF: there was net bicarbonate accumulation of ∼1400 mmol/day with SCUF, compared to 664 to as low as 274 mmol/day during CVVH. The calculations underscore the importance of the relative fluid flow rates as well as the bicarbonate and citrate levels in the various infused solutions. We also discuss how citrate's acid-base effects are potentially complicated by metabolism via gluconeogenic and ketone body pathways.

CONCLUSIONS: These acid-base balance findings emphasize why clinicians must be mindful of the risk of metabolic alkalosis when using continuous renal replacement therapy modalities with low rates of ultrafiltration, which thereby presents a contraindication for using citrate anticoagulation for SCUF.

Keywords: CVVH; SCUF; anticoagulation; citrate; metabolic alkalosis

References

1. Kidney Int. 2005 Jun;67(6):2361-7 - PubMed
2. Am J Kidney Dis. 2005 Nov;46(5):903-7 - PubMed
3. Nephrol Dial Transplant. 2009 Jul;24(7):2244-51 - PubMed
4. J Biol Chem. 2004 Jan 9;279(2):1533-40 - PubMed
5. Blood Purif. 2010;29(2):204-9 - PubMed
6. J Crit Care. 2005 Jun;20(2):155-61 - PubMed
7. Nurs Crit Care. 2007 Mar-Apr;12(2):81-5 - PubMed
8. Int J Nephrol. 2011;2011:748320 - PubMed
9. Crit Care Med. 2009 Feb;37(2):545-52 - PubMed
10. Nephrol Dial Transplant. 2011 Jan;26(1):232-9 - PubMed
11. Nephrol Dial Transplant. 2005 Jul;20(7):1416-21 - PubMed
12. Nephrol Dial Transplant. 2011 Dec;26(12):3882-8 - PubMed
13. Crit Care Med. 2009 Jun;37(6):2018-24 - PubMed
14. Crit Care Med. 2003 Oct;31(10):2450-5 - PubMed
15. Nephrology (Carlton). 2006 Oct;11(5):405-9 - PubMed
16. Nephron Clin Pract. 2004;97(4):c131-6 - PubMed
17. Am J Kidney Dis. 2005 Nov;46(5):908-18 - PubMed
18. Intensive Care Med. 2010 Oct;36(10):1735-43 - PubMed
19. Kidney Int. 1990 Nov;38(5):976-81 - PubMed

Publication Types

• Journal Article